Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Semaglutide, the drug used in Ozempic, has been linked to lowering the risk of Alzheimer's disease in the past. So, it was ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

Dancing the Blues Away' Seen in Brain Imaging in People With Parkinson's Disease, New Study Finds Dec. 18, 2024 — Dancing lowers the depression associated with Parkinson's disease, and the ...

A Colorado Springs family hopes to win what they believe would be a landmark legal verdict by proving to jurors next month ...

A novel wireless photothermal DBS nanosystem uses nanoparticles to target and restore damaged neurons in Parkinson’s disease, ...

Parkinson’s disease is a progressive neurodegenerative disease that destroys substantia nigra dopaminergic neurons, causing tremors, bradykinesia, rigidity, and postural instability. Current treatment ...

Get Instant Summarized Text (Gist) A wireless photothermal deep brain stimulation (DBS) nanosystem, ATB NPs, has been developed to treat Parkinson's disease by targeting dopaminergic neurons. This ...